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ABSTRACT
Isolation, Genetic Characterization and Clinical Application of
Bacteriophages of Pathogenic Bacterial Species
Trever Leon Thurgood
Department of Microbiology and Molecular Biology, BYU
Master of Science
Bacteriophages (phages) are the smallest biological entity on the planet. They provide
vast amounts of valuable knowledge to biologists. Phage genomes are relatively simple
compared to the organisms they infect (prokaryotes) and yet continually point to the complexity
surrounding molecular- and microbiological mechanisms of life. By studying phages we can
learn of the systems of gene expression, protein interaction and DNA organization. Phages are
useful not only from an academic perspective, but may also have useful clinical applications. In
the face of the rise of antibiotic-resistant bacterial “super pathogens”, scientists and researchers
turn to phages as alternative treatments to these types of infections. Phages are capable of
infecting and killing even the deadliest of bacterial pathogens, such as carbapenem-resistant
Enterobacteriaceae (CRE) or Bacillus anthracis, and may prove increasingly useful in the future
for combatting harmful pathogens. This thesis looks at several aspects of phage biology—from
the underlying genetics contributing to phage virulence, to the clinical application of phage
therapy to treat infections. First, a look at CRE-Klebsiella pneumoniae isolates and phages
capable of infecting some strains may reveal a potential therapeutic approach in the future.
Additionally, genomic analysis reveals interesting features that may explain aspects of phage
virulence and evolutionary history. Then, a collection of genetically diverse phages is used in
infection assays on pathogenic strains of Bacillus anthracis to establish the first-reported phages
capable of infecting these strains. Finally, the process of preparing phage samples for therapeutic
application is explored in-depth to conclude with discussion of clinical application. During the
course of these projects over 25 phages were isolated, as many phage genomes were assembled
and annotated, resulting in the preparation of two genome announcements and near-completion
of two publishable first-author papers (chapters II and III). In addition, participation in a variety
of collaborative efforts may lead to a handful of co-author papers and on various topics,
including phage biology and application.

Keywords: bacteriophage, phage, carbapenem-resistant Enterobacteriaceae, Klebsiella
pneumoniae, Bacillus anthracis, phage therapy
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CHAPTER I: Introduction to Bacteriophages and Host
Introduction
Pathogenesis of Enterobacteria and Firmicute bacteria
The first correlation between a specific disease and its causative bacteria was made in
1876 by Robert Koch, who discovered Bacillus anthracis to be the cause of anthrax.1 Since then,
numerous pathogenic bacteria have been discovered. The most basic division of bacterial species
separates bacteria into three main groups based on cell wall structure: Gram-positive and Gramnegative and Acid-fast (Fig. 1-1). Pathogenic species are found in all three groups. Within Grampositive bacteria, the phylum Firmicutes has a number of pathogenic genera that cause serious
human infections including Clostridium, Staphylococcus, Streptococcus, Listeria and Bacillus.
Of the Gram-negative bacteria, the family Enterobacteriaceae, also known as Enterobacteria or
enteric bacteria, consists of many common human
pathogenic genera, including Klebsiella, Escherichia,
Salmonella, Citrobacter, Serratia, Shigella and Yersinia.
Mycobacterium tuberculosis is one of the most well-known
Acid-fast pathogenic species. This proposal focuses on 4
species found across Gram-positive and Gram-negative
bacteria: Klebsiella pneumoniae, Serratia marcescens,
Citrobacter freundii and Bacillus anthracis (see Table 1-1
for taxonomic summary).
B. anthracis is a non-motile, spore-forming, GramFigure 1-1. Distinction between
Gram-positive and Gramnegative cell wall structures.

positive bacterium capable of causing disease in man and
animals. While there is high genetic similarity among
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pathogenic strains, Van Ert, et al. classified B. anthracis strains into 12 phylogenetic clades that
separates them based on single-nucleotide differences.2 One representative from each clade has
been selected to test susceptibility to phage infection. Common to all pathogenic strains is the
production of a tripartite toxin, suitably named anthrax toxin, which is responsible for
pathogenicity in hosts.2 The genes encoding the toxins are found on virulence plasmid pXO1.3
Anthrax toxin is composed of edema factor (EF), lethal factor (LF) and protective antigen (PA),
all of which cooperate to invade and lyse host cells.2,4,5 PA forms a pore on the host cell surface,
while EF and LF are transported through the membrane and carry out fatal enzymatic activities
Table 1-1. Taxonomic summary of bacteria in study.
Bacteria
Bacteria
Bacteria
Domain
Firmicutes
Proteobacteria
Proteobacteria
Phylum
Bacilli
Gammaproteobacteria Gammaproteobacteria
Class
Bacillales
Enterobacteriales
Enterobacteriales
Order
Bacillaceae
Enterobacteriaceae
Enterobacteriaceae
Family
Bacillus
Klebsiella
Serratia
Genus
anthracis
pneumoniae
marcescens
species

Bacteria
Proteobacteria
Gammaproteobacteria
Enterobacteriales
Enterobacteriaceae
Citrobacter
freundii

Figure 1-2. Infection cycle of B. anthracis. Sequestration of plasmid pXO1- and pXO2-containing B.
anthracis to its sporulated form, subsequent inhalation and infection of immune cells. Sporulation is a
reversible process, which is necessary for toxin expression and successive infection.

2

that lead to apoptosis and subsequent necrosis (Fig. 1-2).2,4 Anthrax toxin causes disease by
interfering with host immune cell signaling pathways such as mitogen-activated protein kinase
(MAPK) and chemokine networks, ultimately inhibiting proinflammatory and cellular
transcriptional responses that would otherwise activate immunity cascades.2,4–7 In addition to this
virulence plasmid, pathogenic strains of B. anthracis also contain a second plasmid, pXO2,
encoding genes for a poly-γ-D-glutamic acid capsule that aids in host immune evasion.8,9
Another trait of Bacillus species is the ability to form spores. As a spore, B. anthracis is
estimated to have a half-life of 100 years.10 Spore formation protects the cell from environmental
dangers, including high or low pH, UV radiation, extreme temperatures, desiccation, nutrient
depletion and mutagens.11–13 Sporulation enhances pathogenicity by allowing B. anthracis to
become aerosolized and inhaled by the host (Fig. 1-2). Upon inhalation, alveolar dendritic cells
and macrophages become the point of entry into the host lymphatic and circulatory systems,
leading to rapid sepsis and likely mortality.14–17 This set of molecular mechanisms empowers B.
anthracis to be a formidable pathogen and potential bioweapon.10,18
Pathogenicity of the Enterobacteriaceae species varies greatly from that of Bacillus
anthracis. Many Enterobacteriaceae are opportunistic pathogens that cause secondary infections
in immunocompromised individuals and are one of the main causes of nosocomial infections in
the United States.19 Infection with an enteric bacteria begins with invasion of susceptible tissue.
Common infection sites include lung tissue, catheter entry sites and urinary tract, surgical wound
sites, burn sites and the bloodstream.20 Once introduced into vulnerable sites, pathogenic enteric
bacteria establish infection by adhering to surrounding tissues through adhesive extracellular
components such as pili and fimbriae, adhesins and intimins, and extracellular polysaccharides
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(EPS).20–23 Additional virulence factors include type-III secretion systems that inject toxins and
host signal transduction disruptors that appropriate host metabolic activity.23
Antibiotic-resistance confers protection for bacterial cells
Since the discovery and mass-production of antibiotics in the mid-twentieth century,
antibiotic-resistant strains or serotypes of bacterial species have increased globally.24 While a
number of new classes of antibiotics have been introduced over the past half-century, the rate of
acquired resistance exceeds the rate of discovery.25 This precarious reality merits the study of
alternative treatments to bacterial infections, which remain among the leading causes of death
worldwide.26
Carbapenems are a sub-class of
ß-lactams capable of potent
antimicrobial activity. They are
defined as the 4:5 fused ring lactam of
penicillins with a double bond between
C-2 and C-3, but with the substitution
of carbon for sulfur at C-1 (Fig. 1-3).27
The expanded structure of
carbapenems from penicillins directly
improves effectiveness against
microbes, as ß-lactamases are less

Figure 1-3. Carbapenems. General structure (a) and
specific examples of carbapenems (b-d). Additions in Rgroup side-chains can be as simple as a methyl group or
more complex structures that directly affect effectiveness
in killing bacteria and susceptibility to ß-lactamases.

effective in hydrolyzing the molecule due to their irregular structure. In modern medicine,
carbapenems have served as “last-resort” antibiotics in order to minimize development of
antibiotic-resistance. Nonetheless, like every preceding class of antibiotics, continuous exposure
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of bacteria to these compounds has yielded resistance, whether through intrinsic or acquired
mechanisms.27,28 These mechanisms of resistance-acquisition are endemic within
Enterobacteriaceae and are leading to increasing numbers of long-term infections and deaths per
year.24,29,30 These bacteria, Carbapenem-resistant Enterobacteriaceae (CRE), have been named
as a top health concern by the CDC. Furthermore, horizontal gene transfer has contributed to
both the onset and worsening of the antibiotic crisis, with critical resistance genes passing
between even the most unrelated bacteria.27–31 There have not been, however, any reported
clinical cases of antibiotic-resistant B. anthracis infections. Yet, the ease of genetic engineering
may also place this potential weapon on the list of antibiotic-resistant bacteria.
Bacteriophages differ drastically from antibiotics in antimicrobial mechanisms of action
While phages have been known since the beginning of the twentieth century, even before
the advent of antibiotics, their use in Westernized medicine has been limited.32 Nevertheless, in
the face of spreading antibiotic-resistance, phage therapy is again garnering interest. In contrast
to antibiotic compounds, phages are independent biological entities capable of permanently
altering bacterial lifecycle and genetics. Also dissimilar to antibiotics, phages are capable of coevolution with their host, and undergo genomic alterations favorable to maintain virulence.33
These phenomena are essential for the successful infection of the host by a phage.
Phage infection begins with virion adsorption onto the host cell via recognition of
bacterial surface components. This surface component is typically a trans-membrane protein or
signal receptor, though surface enzymes, transport channels, pili, flagella, capsular elements,
specific moieties of LPS on Gram-negative bacteria as well as teichoic acids in Gram-positive
hosts, can serve as targets.34 Host targets are recognized by the phage’s tail fibers, which serve as
attachment points for the viral particle. Post- adsorption to the cell surface, the phage undergo a
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conformational change that
involves injection of viral
nucleic acid into the bacterial
cell. Upon entry to the cell, the
phage can initiate one of two
lifestyles: lytic or lysogenic. In
the former, successful infection
relies on the timed order of gene
Figure 1-4. Lytic versus lysogenic phage lifecycle. (A)
Injection of phage DNA into the host cell, appropriation of host
metabolic machinery with use of transcription factors, gene
expression and virion production, lysis of the host and
subsequent spread into the environment. (B) Injection of phage
nucleic acid into the host cell, cleavage of host genome,
integration of phage DNA into host chromosome, and
subsequent DNA proliferation. Integrated phage DNA now
considered a prophage.

expression, commonly referred
to as early-, middle- and lategenes. Timed gene expression is
essential for successful host
infection, as phage lifecycle is

dependent on specific proteins being expressed at different timepoints during the infection
period. For example, transcriptional regulators designed to take over bacterial metabolic
machinery are immediately expressed, which directs bacterial polymerases and ribosomes to
replicate and express the viral genome. Then, as the infection cycle progresses, structural and
enzymatic proteins are expressed (Fig. 1-4A). In the lysogenic lifecycle, phages initiate infection
in a similar manner, but diverge in lifestyle by inserting the viral genome into the host genome
(Fig. 1-4B). This can occur via site-specific recombination (SSR) or via homologous
recombination (HR).35 Phage DNA then proliferates with the host and can remain in the host
genome permanently.
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Bacteria susceptible to
infection by a phage are defined as
being part of the phage’s “host range”.
As bacteria acquire mutations, phage
recognition sites may become
unrecognizable to the phage’s tail
fibers such that the phage is no longer
able to adsorb onto the cell surface to
initiate infection, and the bacterium is
no longer within the host range of the
phage. Regardless, as a bacterium
evolves out of the host range of one
particular phage, it likely will evolve
into the host range of a different phage
(Fig. 1-5). Bacteriophages outnumber
bacteria by ten to one.33 Thus, it
almost assuredly follows that there is a
phage capable of infecting every
bacterial species, strain and serotype.

Figure 1-5. Mutation prevents one phage infection,
permitting another. (A) The red phage has tail fibers
capable of recognizing the receptor protein (labeled RP1)
and adsorbs to the cell surface. (B) After adsorption, the
phage infection cycle begins. (C) RP1 is randomly
mutated, becoming ∆RP1, and is no longer recognizable
by the red phage’s tail fibers, thus preventing adsorption
and infection initiation; (D) however, the mutation now
makes ∆RP1 recognizable by the blue phage, which can
adsorb and initiate its infection cycle.

It is for this reason that phage therapy is of great interest. When a bacterial strain becomes
resistant to antibiotics, without alternative treatment, a patient is likely stuck with the infection
indefinitely; however, utilization of a phage’s natural host range may serve as an alternative
antimicrobial to otherwise resistant bacteria.
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Aside from surface protein mutations that confer resistance to bacteriophage infection,
capsule expression and biofilm production may also inhibit phage infections. For example, the
poly-γ-D-glutamic acid capsule of B. anthracis may play a role in protection against phage
recognition of the host cell wall. In 2013, Negus, et al. found that capsule production by B.
anthracis prevented phage infection of host cells, contradicting previous studies reporting that
capsule production played little to no part in inhibiting phage infections.36 Together, these
studies lead us to question which phages have the ability to infect capsule-producing strains of B.
anthracis.
Bacteriophages are capable of infecting antibiotic-resistant bacteria
Bacteria that become resistant to antibiotics have developed one or more mutations that
change the effectiveness of some types of antibiotics. For example, a bacterium may alter some
essential metabolic pathway inhibited by the antibiotic, while others may develop efflux pumps
that specifically target antibiotic compounds.37 These adaptations are generally acquired via
plasmid transfer.37 Plasmid acquisition and retention generally come at a cost to the bacteria, but
when the plasmid confers resistance to otherwise fatal antibiotics, the benefits outweigh the
cost.38 Despite this beneficiary fitness tradeoff, however, phage challenge can alter the fitness
cost of maintaining antibiotic-resistant pathways. In a 2016 study, a Pseudomonas aeruginosa
bacteriophage, OMKO1, that targets bacterial outer membrane porin M (OprM) which is used in
a multi-drug efflux system, forced a mutation of the receptor leading to increased sensitivity to
antibiotics.32 Conversely, phages have also been known to transfer antibiotic-resistance genes
between bacteria, though no phages are currently known to be the source of resistance genes.39
Such occurrences are important considerations in phage therapies, so as not to strengthen
resident bacteria in an infected site, when the aim is to eradicate them. Furthermore, because
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resistance to phage infection can develop within a bacterial community, having genetically
diverse phages can increase the chances of a successful treatment (i.e. due to the fact that phages
use different entry mechanisms, and a bacterial population is unlikely to spontaneously mutate
multiple receptors at once).
Summary of aims to elucidate bacteriophage infection mechanisms
For the reasons previously detailed, it is the purpose of this project to isolate, sequence
and genetically characterize phages capable of infecting a variety of clinical multi-drug resistant
bacterial strains. The strains in question include a variety of CREs (Klebsiella pnuemoniae,
Serratia marcescens, Citrobacter freundii) as well as the Gram-positive, pathogenic Bacillus
anthracis strains, which heretofore have never been reported to be susceptible to any phage
infections outside of the Gamma phage cluster. We seek to uncover some of the mechanisms
used by phages to infect antibiotic-resistant bacterial strains, possibly shedding light on novel
phage molecular genetics. These studies lead to results that may be clinically useful for treatment
of antibiotic-resistant infections via phage therapy. Additionally, the results may have
implications beyond the scope of these studies. The specific aims for this project are as follows:
Evaluate phage efficacy against clinical isolates of Klebsiella pneumoniae
Using a library of drug-resistant clinical isolates of Klebsiella pneumoniae, susceptibility
to bacteriophage infection is analyzed. Then, genomic analysis serves to identify unique
properties that may elucidate phage infection mechanisms.
Establish host range of Bacillus anthracis bacteriophages against pathogenic strains
Using a collection of newly-isolated B. anthracis bacteriophages, define the host range
against pathogenic strains of B. anthracis for each viral genetic family represented by phages
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within the collection. A sub-aim includes genomic analysis of phage genetic makeup to further
characterize our collection in relation to known phages.
Isolate, prepare and administer phages for treatment of a Serratia marcescens infection
Under the guidance of the FDA, phages isolated from sewage using a clinical isolate of S.
marcescens is be purified, amplified and purged of endotoxin in preparation for use in treatment
of a human infection. Genomic analysis and RNAseq of at least one of these phages will reveal
genes used during the course of infection.
Experimental plan
Isolate novel phages against clinical and non-clinical strains
Because the bacterial strains being used in this proposal are human pathogens, strains and
phages should be obtained from a source abundant with the pathogens. Untreated sewage, also
known as primary influent or raw water, contains a high concentration of these pathogens and
their relevant phages. Phages, whether lytic or lysogenic, require a host to replicate and are found
where bacteria are abundant. By incubating bacteria-of-choice with raw sewage, phages capable
of infecting the host bacteria will enumerate. Centrifugation and filtration remove debris and
unwanted bacteria, leaving behind phage in the lysate. This lysate can be spotted onto the host
bacteria or used in a plaque assay to produce isolated plaques. In either case, plaque purification
must be done a minimum of three times for the purpose of “purifying” phage from additional
virions, toxins, and unwanted pathogens from the original enrichment culture.
Determine susceptibility of multi-resistant K. pneumoniae strains to phage infection
The wet-lab portion of this aim was completed by Olivia Tateoka in summer 2018. Due
to sequencing concerns revealing multiple phage genomes in a single sample, phages were
separated via plaque purification, phage presence confirmed with PCR and her results replicated.
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Determine host range of B. anthracis phages against pathogenic strains
Because B. anthracis is considered a “select pathogen” by the CDC, there are stringent
regulations surrounding its use. For this reason, all pathogenic B. anthracis work is be done in
the BSL3 facility following all safety
protocols established by BYU and the
CDC. The extent of the host range
testing is to determine the variety of
phages that can infect different strains
of B. anthracis. Van Ert, et al.,
classified over 400 clinical B. anthracis
strains into twelve phylogenetic
clades.40 In order to account for this
genetic variability, we have selected
one strain from each clade as a
representative host to test infectability

Figure 1-6. Dot plot comparison of B. anthracis
phages. Bolded names are already-published phages.
Colored squares represent clusters, with sub-clusters
separated by dotted lines. Individual phage genomes are
separated by black lines (horizontal and vertical).
Diagonal lines appear when there is >50% nucleotide
similarity between phage genome segments.

by our phages. Additionally, of our 24 B. anthracis phages, they can be separated into 6 clusters
and 2 sub-clusters, each of which is genetically distinct from the others (Fig. 1-6). Therefore, to
account for all variability, a representative phage from each cluster has been selected to infect all
twelve strains of B. anthracis.
Preliminary results conducted by Hyrum Shumway show that almost all phages are
capable of infecting all strains. This finding is particularly interesting because all of the phages
used in the study were isolated on the Sterne strain of B. anthracis. Sterne is missing the γ-D-
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glutamic acid capsule-encoding plasmid, pXO2, whereas the pathogenic strains all produce the
capsule. This variance in surface structure does not change susceptibility to phage infection as
would be expected and merits further investigation. Additionally, we want to know if the phages
are capable of infecting the sporulated form of B. anthracis. In contrast, spores produce unique
surface components when compared to vegetative cells, which may alter phage recognition sites.
Genetically characterize phage genomes with bioinformatic tools
While phage therapy is the clinical application of phage research, genomic analyses are
critical to understanding the underlying molecular genetics driving phage lifecycle. Besides
genome sequencing, tools like Phamerator maps, Splitstrees, dot plot comparisons, individual
gene sequence alignments, motif identification, and BLAST comparisons elucidate some of these
mechanisms. Phamerator maps highlight differences between highly related phage genomes, as
well as similarities between highly different phage genomes. Phamerator identifies conserved
domains in predicted protein products and categorizes phage genes accordingly. A table of
protein products contained within the gene products included in the analysis can be exported and
converted to the file-type necessary for SplitsTree usage. SplitsTree phylogenies compare only
the presence of protein families in determining relatedness among organisms, rather than the
standard way of comparing nucleotide or amino acid sequences. While a dot plot and SplitsTree
may predict overall phylogeny, alignments of individual amino acid sequences from select
proteins and subsequent phylogenetic tree production can indicate different relationships among
organisms. This is particularly pertinent within phage biology, as gene transfer and genome
rearrangements are highly common. Thus, MEGA X and Kalign is be used to produce
phylogenetic trees for additional analyses.41 Multiple Em for Motif Elicitation (MEME) is used
to predict DNA motifs within phage genomes.42 DNA motifs tend to indicate protein-binding
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sites within a genome, and predicted motifs found in the phage genomes of this study are
compared to known motifs through prokaryotic motif databases using TOMTOM.43
By performing these analyses we expect to find a number of interesting genomic artifacts
that may lead to new understanding of phage genetics. The K. pneumoniae and B. anthracis
phages may contain clues that explain why some phages are capable of infecting certain strains,
while others are not. Combined with wet lab techniques, genomic analyses can help identify
patterns that coincide with observable patterns (phage infections, in this case) and may provide
insights into gene functionality.
RNAseq analysis reveals early, middle and late genes required for infection
A crucial aspect of phage virulence is the expression of essential genes at specific time
points during the infection cycle. While variability exists between phages, general classes of
proteins are universally expressed at early, middle and late timepoints. Sequencing RNA
extracted at early, middle and late timepoints during an infection can provide clues as to the
functions of otherwise unknown gene products. Such analysis is particularly interesting with
completely novel phages, those which have completely unique genomes. From our own
collection, we have selected several such phages, one of which is capable of infecting a multiresistant strain of S. marcescens. RNAseq analysis provides insight into the lytic cycle of the
phage and aids in further characterization through protein identification.
Under FDA guidelines, prepare phages for clinical therapy
Our lab was contacted in 2018 by several doctors and a veterinarian seeking assistance in
isolating and preparing phages to fight clinical infections. Of these, two requested complete
preparation of the phages, from isolation to amplification and elimination of bacterial endotoxin.
As Gram-negative bacteria proliferate, they shed LPS into the surrounding culture. LPS is a
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powerful inducer of the innate immune system, and a phage therapy preparation, if left untreated
can lead to septic shock and death.44,45 With phage infection, additional bacterial lysis occurs,
thus increasing the concentration of LPS in the lysate. The human immune system innately
responds to and targets LPS, even at low concentrations.46 Therefore, it is critical that all LPS is
removed from a phage lysate before therapeutic use. There are two techniques reported to
complete this process with high degrees of efficiency. These are used in the process of preparing
phage therapies. The first method is a polyethylene glycol (PEG) 8000 high-speed
centrifugation-precipitation protocol, adapted from the Baker lab at University of Washington.47
The PEG aids in phage conglomeration, which then pellet at high speeds (12,000 x g) and
separates them from the endotoxin-containing supernatant. The supernatant is removed, and the
phage resuspended in endotoxin-free buffer. The second method involves organic solvent
extraction of the LPS, typically 1-butanol or 1-octanol, and phase separation.48 Afterwards, the
organic solvent is removed through ethanol and sodium dialysis. The PEG precipitation is the
faster protocol while the organic solvent phase separation protocol reports lower residual
endotoxin levels. In our lab, we use the ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit
(GenScript; New Jersey, USA) that utilizes limulus amoebocyte lysate and chromogenic
substrate to quantify LPS levels, before reporting to the FDA for treatment approval.
Potential problems
Between the wet lab techniques and computational analyses, there are a number of
potential problems that may arise during the process of characterization. By comparing phage
genomic elements to already-established databases, there is a risk of missing novel genetic
components. For example, MEME predicts the presence of motifs, some of which may be novel,
but by comparing them to known prokaryotic motifs through TOMTOM, some of the motifs may
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not match recognized motifs and appear statistically insignificant. Without extensive lab work to
characterize novel motifs, their functions will continue to be unknown.
Additionally, working with pathogenic strains with high mortality rates of infection (B.
anthracis) or with known multi-drug resistance (Enterobacteriaceae) is extremely dangerous. As
such, many safety precautions are put into place for the protection of both the experimenters and
the general lab population. Increased safety measures can decrease efficiency, particularly in
timed assays, such as plaque assays. Therefore, careful planning is required before initiation of
experimental procedures. In working with B. anthracis, for example, a BSL3 facility is required.
All materials must be prepared and ready-for-use before entering the facility. Fortunately,
familiarity with the facility can eliminate a plethora of problems.
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CHAPTER II: Evaluation of Bacteriophage Against Clinical Isolates of Carbapenem-Resistant
Enterobacteriaceae
Authors: Trever Thurgood, Olivia B. Tateoka, Richard A. Robison and Julianne H. Grose
This chapter is taken from a publication in preparation for submission at the time of writing of
this thesis.
Abstract
Bacteriophage (phage) therapy was an effective treatment against bacterial pathogens that
was discovered nearly a century ago but was quickly abandoned in the western world with the
advent of antibiotics. There has been renewed interest in phage therapy due to increasing
occurrence of antibiotic resistant bacterial pathogens such as carbapenem-resistant
Enterobacteriaceae (CRE), which currently have a fifty percent mortality rate. To explore the
possibility of phage therapy as treatment for these multi-drug resistant infections, fourteen novel
phages were tested against clinical isolates of carbapenem-resistant Klebsiella pneumoniae.
Several of the phages were able to infect these clinical isolates suggesting that phage therapy
may be a viable option for treating CREs. Genomic analyses indicates some of the genetic
components that could potentially be responsible for the ability of the phages to infect these
bacterial hosts.
Introduction
Klebsiella pneumoniae, a member of the Enterobacteriaceae family, is one of the most
common Gram-negative bacteria responsible for hospital-acquired infections, frequently causing
urinary tract infections, pneumonia, and bacteremia49,50. As opportunistic pathogens, K.
pneumoniae primarily attack immunocompromised, hospitalized individuals suffering from
severe underlying diseases, such as diabetes. In the United States, Klebsiella spp. accounts for 3-
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7% of all nosocomial bacterial infections, placing them among the most clinically significant
pathogens found in hospitals.50
A well-recognized difficulty in treating most Enterobacteriaceae infections is their
resistance to broad-spectrum antimicrobials.51 Classically, carbapenems have been the terminal
antibiotic in treating these types of infections and carbapenem-resistant strains have been
relatively uncommon, until recently.51 The emergence of carbapenemases that have direct
carbapenem-hydrolyzing activity has contributed to an increased prevalence of carbapenemresistant Enterobacteriaceae (CRE), a high mortality rate associated with CRE infections, and
the potential for widespread transmission of carbapenem-resistance through mobile genetic
elements.51–54 These issues, combined with the limited therapeutic options available to treat
patients with CRE infections, have led to the necessity of alternative treatments, such as phage
therapy.
Bacteriophages (phages), are viruses that infect bacteria. Due to the ability to kill their
bacterial hosts, phages were first used successfully to treat bacterial infections a decade before
penicillin was discovered; however, the ease of production and the broad-spectrum action of
antibiotics became more efficient than phage therapy.55-56 Thus, the advent of antibiotics led to
the cessation of phage-based therapies in the Western world, although they continued to be
practiced in Eastern Europe and in the former Soviet Union.57
Phage therapy has been successful against antibiotic-resistant strains due to the distinct
mechanisms by which viruses infect and kill bacterial cells. Phages are often very specific for the
species, or even strain, of bacteria that they infect through the recognition of a receptor on the
surface that initiates infection. Their DNA is injected into the cell, making them capable of
transferring genetic material and altering host DNA through horizontal gene transfer. The
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majority of phages studied to date are strictly lytic, using the cell to produce progeny which are
released upon lysis 57,58, however some phages can also integrate directly into the host
chromosome in what is called the lysogenic cycle of a temperate phage.58,59 Lysogenic phage are
often responsible for the pathogenicity of a particular bacterium, for example pathogenic strains
of Corynebacterium diphtheriae, Vibrio cholerae, and E. coli wherein the temperate phage
carries the bacterial toxin. Thus, phages for use in phage therapy must be adequately screened for
a lytic nature as well as the lack of genes that may contribute to pathogenicity.
An additional benefit of phage therapy includes the relatively limited host range, or
natural target cells, of individual phages. By limiting phage therapy to include phages only
capable of infecting a single species of bacteria, such as an invasive, antibiotic-resistant strain,
the natural host range of the phage will target the harmful bacteria while protecting the normal
microflora that is vital to health.59–61 Phage therapy has already begun to be used in agriculture
and food industries, but use in human infections is limited to a case-by-case basis.57 A number of
in vitro studies have shown that phage have the potential to lyse targeted bacterial pathogens.61–63
In this study, we evaluated lytic phages against clinical isolates of carbapenem-resistant
Klebsiella pneumoniae.
Materials and methods
Bacterial strains and culture conditions
K. pneumoniae ATCC 13883 was used as a control organism and was purchased from
American Type Culture Collection (ATCC, Manassas, VA, USA). Clinical isolates of
carbapenem-resistant K. pneumoniae obtained from the CDC (Centers for Disease Control and
Prevention, Atlanta, GA, USA) were designated as K. pneumoniae 1002002, K. pneumoniae
1300761, K. pneumoniae 20080030, and K. pneumoniae 1002235. Additional carbapenem-
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resistant clinical isolates were obtained from hospital patients at Intermountain Healthcare in
Utah County, UT, USA and were designated as K. pneumoniae IHC#1, K. pneumoniae IHC#2,
and K. pneumoniae IHC#3. All strains were cultured in Luria-Bertani (LB) broth (Fisher
BioReagents, Fair Lawn, NJ, USA) at 37ºC and grown overnight. Following the overnight
culturing, strains were aliquoted at 1:10 dilution into LB broth and allowed to recover for 1 hour,
ensuring that the bacteria were in exponential phase for subsequent assays.
Antibiotic susceptibility testing (AST)
Testing was done using the microdilution method in 96 well plates to find the minimum
inhibitory concentration following the Clinical and Laboratory Standards Institute (CLSI)
guidelines.64 CLSI susceptibility breakpoints (M100-S27) were used to determine
susceptibility/resistance status. All of the strains were tested against ampicillin, gentamicin,
cefazolin, imipenem, chloramphenicol, and tetracycline. The antibiotics were prepared in twofold dilutions (e.g. 2,4, 6, 8, and 16 μg/ml). The strains were incubated overnight in cationadjusted Mueller-Hinton broth (MHB, Sigma-Aldrich, St. Louis, MO, USA) in a shaking

incubator at 37ºC. Following overnight culturing, the strains were subcultured to reach an
OD600 of 0.01. MHB was mixed with antibiotic and then the subcultured bacteria were added to
the well. The plates were incubated for 18 hours at 37ºC and the presence or absence of turbidity
indicated the susceptibility of the strain to the antibiotic.
Bacteriophage propagation and titer assay
All fourteen bacteriophages used in this study were isolated by the Phage Hunters
program at Brigham Young University (BYU, Provo, UT, USA). All phages were isolated from
untreated waste water on K. pneumoniae ATCC 13883. K. pneumoniae 13883 was grown
overnight at 37ºC in LB in a shaking incubator. Enrichment cultures were created by adding 1
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mL of overnight culture into 9 mL of LB, followed by the addition of 100 μL of phage lysate

(provided by Phage Hunters) into the 1:10 bacterial dilution and grown for 24 hours with shaking
at 37ºC. The enrichment cultures were centrifuged at 6000 x g for 20 minutes, and the
supernatant was filtered through a 0.2-μm filter (Millipore) to remove bacterial debris. To verify
the presence of phage and determine the titer, the supernatant was serially diluted (1:10) to 108
dilution, and 50 μL of diluted supernatant was incubated with 400 μL host strain for 30 minutes
at room temperature. After incubation, 4.5 mL of 1% molten LB agar was added to the phage

and host strain and was overlaid on a LB agar plate. The plates were incubated at 37ºC for 18-24
hours. Following the incubation period, plaques on the plates were counted to calculate phage
titer.
Bacterial challenge assay
All the strains were incubated overnight in 10 mL of LB broth at 37ºC with shaking.
After the overnight incubation, the cultures were diluted 1:10 in LB broth and then allowed to
recover for 1 hour, until OD600 reached 0.04-0.05. The strains were aliquoted at 400 μL each and
50 μL of phage were added and incubated for 30 minutes at room temperature. After incubation,
4.5 mL of 1% molten LB agar was added to the mix and overlaid on a LB agar plate. The plates
were incubated for 18-24 hours at 37ºC. The presence of plaques indicated the infectivity of
phage. This challenge assay was performed in triplicate.
Phage sequencing and computational analyses
All phages were propagated to reach a high titer, following which the DNA was isolated
using the Norgen phage DNA isolation kit (Norgen, Canada). Quality of isolated DNA was
checked with gel electrophoresis (1% w/v agarose) and quantified with PicoGreen DNA
quantification kit (Thermo Fisher Scientific, Waltham, MA, USA). The DNA was then
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sequenced using Illumina sequencing and the genomes assembled with Geneious R8.1.65
Genome annotations and corrections were made manually using DNA Master 1, Basic Local
Alignment Search Tool (BLAST) 2 searches and GeneMark coding potential prediction
software.66
Genome comparisons were done by aligning phage nucleotide sequences on Gepard to
create the dot plot.67 The GenBank-formatted files of annotated genomes were used in tandem
with PhamDB in an online interface to generate a database usable by Phamerator, an open-source
program used to create pham maps.68,69 Kalign was used to generate average nucleotide identity
(ANI) tables for the phages.70 SplitsTree was used to create protein-based phylogenetic grouping
of the phages by exporting the pham table of conserved proteins (available on Phamerator) to
JanusA, which converts the table to a nexus (.nex) file-type required for SplitsTree.71 The
maximum likelihood phylogenetic tree of the phages’ large terminase subunits was assembled
with MEGA X after aligning the amino acid sequences on Geneious R8.1.41,65
tRNA genes were predicted by running phage genomes through tRNAscan-SE.72 DNA
motifs in the phage genomes were predicted using Multiple Em for Motif Elicitation (MEME)
accessed through the Pasteur Institute’s iteration of the Galaxy server, and predicted motifs were
run through the TomTom motif database and comparison software to determine potential motif
functions.43,73,74 TomTom settings were set to compare motifs to the Prokaryotic Database of
Gene Regulation (PRODORIC) and all motif functions are found on this database.75 The p-value
cutoff for accepting MEME motif predictions as well as the TomTom comparisons in the
analysis was 1.00E-3.

1
2

http://cobamide2.bio.pitt.edu/
https://blast.ncbi.nlm.nih.gov/Blast.cgi
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Results
Antibiotic susceptibility testing
The results of a minimal inhibitory concentration (MIC) analysis of several clinical Klebsiella
strains are found in Table 1, which indicate that the majority of the isolates are not only
carbapenem-resistant but have multi-drug resistance as well. Six of the seven isolates exhibited
resistance to imipenem with IHC #2 displaying an intermediate resistance, whereas isolate
2008030 showed resistance to imipenem. All of the isolates showed resistance to ampicillin
(AMP) where concentrations as high as 128 μg/mL were insufficient to inhibit bacterial growth.
Similarly, all isolates were resistant to cefazolin (CEF) up to 32 μg/mL. IHC #2 was the only

isolate susceptible to gentamicin (GEN), where the other isolates were resistant up to 64 μg/mL.
Five of the isolates were resistant to chloramphenicol (CAM), with varying amounts of

resistance, depending on antibiotic concentration. Six of the seven isolates were resistant to
tetracycline (TET), with isolate 1300761 showing susceptibility.
Table 2-1: Antibiotic susceptibility testing results.

AMP (≥32)

GEN (≥16)

IMI (≥4)

CAM

TET (≥16)

IHC #1

R (>128)

CEF (≥ 8)
R (>32)

R (>64)

R (>16)

R

R (>64)

IHC #2

R (>128)

R (>32)

S (2)

I

R (>128)

R

IHC #3

R (>128)

R (>32)

R (>64)

R (>16)

R

R

2008030

R (>128)

R (>32)

R (>64)

S (0.25)

R (>64)

R (>64)

1002002

R (>128)

R (>32)

R (>64)

R (>64)

I

R (>64)

1002235

R (>128)

R (>32)

R (>64)

R (>64)

R

R

1300761

R (>128)

R (>32)

R (>64)

R (>64)

I

S

R, resistant; S, susceptible; I, intermediate; AMP, ampicillin; CEF, cefazolin; GEN, gentamicin;
IMI, imipenem; CAM, chloramphenicol; TET, tetracycline
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Characterization of fourteen phages that infect Klebsiella pneumoniae
Fourteen recently isolated and sequenced Klebsiella phages were analyzed in this study
(Table 2). Whole-genome nucleotide dot plot of the phage genomes is commonly used to assess
phage relationships due to its ability to detect relationships among even mosaic, rearranged
genomes. A dot plot of these fourteen phages produced by Gepard67 displays shows clear
grouping into five distinct “clusters”, typically defined as phages displaying similarity over 50%
of their genome.76–78 Combined with the ANI matrix (supplementary table 1), it becomes
obvious that genetic similarity within phage clusters is high, and that diversity between clusters
is extensive. These clusters include KaAlpha and Potts1 which are distant relatives (61.48%
ANI) , a singleton phage KaOmega, phages Domnhall, IMGroot, Alina, Penguinator, KingDDD,
Call and SegesCirculi which are close relatives sharing >85% ANI, a singleton phage Chronis,
and phages Sibilus, NahiliMali and Emp27 of which EMP27 is the most divergent.
Table 2-2: A list of the fourteen phages analyzed in this study. Includes GenBank accession
number and approximate genome size.
Full Phage Name

GenBank Accession Number Genome Size (kbp)

vB_KpnM_KaAlpha

MN013084

172.3

vB_KpnM_Potts1

MN013081

169.4

vB_KpnM_KaOmega

MN013077

149.5

vB_KpnS_Domnhall

MN013075

54.4

vB_KpnS_IMGroot

MN013076

52.9

vB_KpnS_Alina

MN013083

51.8

vB_KpnS_Penguinator

MN013087

51.7

vB_KpnS_KingDDD

MN013078

51.6

vB_KpnS_Call

MN013079

51.5

vB_KpnS_SegesCirculi

MN013080

50.7

vB_Kpn_Chronis

MN013086

45.7

vB_KpnP_Sibilus

MN013082

40.2

vB_KpnP_NahiliMali

MN013085

39.6

vB_KpnP_Emp27

MN013074

38.6
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Figure 2-1. Gepard dot plot of K. pneumoniae phages used in this study. A “cluster” is
designated when phages share >50% nucleotide identity and is indicated on the dot plot by solid
black, diagonal lines. Phage names are written down the side of the plot, separated on the graph by
lines. Orange lines (vertical and horizontal) separate clusters, while blue lines separate individual
phage genomes. Colored squares indicate “clusters”, which are phages with high nucleotide
similarity.

A Phamerator68,69 map was constructed to analyze proteomic similarity between the phages
(Fig. 2-2). The coloring in the map between genomes highlights nucleotide similar regions between
genomes, and color-coded boxes indicate homologous gene products from the same protein family.
Gene products without color do not have homologous gene products in this data set, thus, genomes
with the fewest colors (such as KaOmega and Chronis) are the most unique. In addition to
distinguishing unique phages, this alignment also makes clear the differences between highly
similar phages. In comparing phages Domnhall and IMGroot, for example, insertion, duplication

24

and rearrangement events are visible on the right half of the genome in IMGroot when compared
with Domnhall. In comparing all the phages of this cluster, the beginning of the genomes (left)
appears to be fairly conserved, with little variation in the sequences. Towards the ends of the
genomes (right), however, there is increased variability, evidenced by numerous indels and at least
one inversion event found in IMGroot.

Figure 2-2. Phamerator map of K. pneumoniae phages used in this study. Phamerator maps compare
nucleotide and protein sequences. The central bar represents the phage genome. The bars above and below
the genome represent gene products. Proteins from the same family are colored the same. Nucleotide
sequences with >50% identity are connected by purple segments. Coloring of names matches dot plot
groupings. Larger image in supplementary data (S1).

In contrast to the nucleotide-based genomic comparisons of Gepard, SplitsTree79 was
used to construct a phylogenetic tree from the protein families identified by Phamerator. The
SplitsTree created for these phages shows the same five phage clusters as the dot plot and
Phamerator map (Fig. 2-3). The SplitsTree map also includes branching sites between the phages
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that may point towards potential evolutionarily significant relationships. For this group of
phages, most splits occur at the base of the tree, with limited branching occurring within
individual clusters suggesting they are very distantly related clusters of phages.
To compare the predicted evolutionary relationship between the phages as well as their

Figure 2-3. SplitsTree map of K. pneumoniae phages used in this study. Phages are grouped
based solely off of predicted proteins. Grouping is similar to dot plot classification (shown by
colors). Larger image in supplementary data (S2).

DNA packaging strategy, the amino acid sequences for the large terminase subunits from each
phage were aligned and run through MEGA X software to calculate the maximum-likelihood
tree (Fig. 2-4).41 The maximum-likelihood tree, similar to the SplitsTree, predicts most major
branching towards the base of the tree, with few splits occurring more recently at the ends of the
branches. In contrast to the SplitsTree, however, the major grouping differs in which phage
26

phamilies share a common ancestor. The SplitsTree indicates that Chronis shares a very distant
proteomic relationship with the Domnhall cluster, and a very early split with the Sibilus cluster at
the base of the tree. The MEGA X large terminase subunit maximum-likelihood tree, however,
places Chronis and the KaAlpha cluster under a common ancestor that previously branched from
the Sibilus clusters, indicative of common DNA packaging strategies. Individual proteins used
for phylogenetic computation that differ from whole-proteome phylogeny point towards apparent
mosaicism displayed in the phage phamilies.80,81

Figure 2-4. Evolutionary analysis by Maximum Likelihood method. The evolutionary history
was inferred by using the Maximum Likelihood method and JTT matrix-based model (Jones, et al.,
1992). The tree with the highest log likelihood (-8891.46) is shown. Initial tree(s) for the heuristic
search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of
pairwise distances estimated using a JTT model, and then selecting the topology with superior log
likelihood value. The tree is drawn to scale, with branch lengths measured in the number of
substitutions per site. This analysis involved fourteen amino acid sequences. There were a total of 796
positions in the final dataset. Evolutionary analyses were conducted in MEGA X (Kumar, et al.,
2018; Felsenstein, J., 1985).
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Analysis of the proteins encoded by these fourteen phages did not reveal any obviously
pathogenic genes, such as toxins, biofilm production genes or antibiotic resistance genes. The
presence of tRNA genes was detected in only four of the phages: KaAlpha (19), Potts1 (7),
KaOmega (20) and Chronis (1). The tRNA genes all occurred in their respective genomes in
grouped segments of <4000bp. The predicted tRNA sequences were compared to the Klebsiella
pneumoniae codon usage table from Codon Usage Tabulated from GenBank (CUTG), accessed
online via FTP. 3 One isotype of tRNA, an asparagine-charged tRNA with anticodon 5’-GUU-3’,
was found in all four genomes, though the coding sequences were different in all four. All seven
of the tRNAs in Potts1 and the lone tRNA gene in Chronis encode A/T-rich anticodons (at least
2 out of 3 nucleotides) which varies from Klebsiella pneumoniae codon preference for G/Ccontaining codons (see database table). tRNAs with anticodons 5’-UUU-3’ and 5’-CAT-3’ are
found in three of the genomes (KaAlpha, Potts1 and KaOmega) and match some of the most
frequently used codons in K. pneumoniae (29.4 and 25.5 out of 1000 codons, respectively).
DNA motifs found within the genomes frequently matched regulatory elements from
Enterobacteriales species, as well as a number of hits from Mycobacterium, Pseudomonas and
Bacillus, but few had p-values of significance. KaAlpha predicted motifs had best matches to
GntR glucose-regulating motifs of Pseudomonales and Burkholderiales families (p-value 8.20E04), E. coli outer membrane protein synthesis (OmpR) operon motif (p-value 5.55E-04), and
DevR-DevS two-component system in Mycobacterium tuberculosis. KaOmega contained motifs
implicated in E. coli metabolism (MhpR and GlnG; p-values 1.85E-04 and 4.39E-04,
respectively) as well as a Pseudomonas putida integration host factor protein binding site (pvalue 5.49E-04). Domnhall showed motifs matching E. coli LacI operon family CytR protein-

3

Accessed at https://www.kazusa.or.jp/codon/
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binding site (p-value 7.35E-04) and Enterobacteriales multi-antibiotic resistance protein (MarA)
binding-site (p-value 1.73E-07).
Temperate versus lytic phage analysis
The most common methods for determining if phages are capable of forming bacterial
lysogens are to 1) isolate phage resistant bacterial lysogens which result upon phage integration
into the host, 2) observe turbid plaques, particularly those with a bacterial lawn in the center
containing phage resistant bacterial colonies, 3) identify integrases in the phage genomes,
required for integrating into the host genome, and 4) finding close phage relatives in sequenced
bacterial genomes. Since wet lab techniques can be biased by laboratory versus environmental
conditions and no turbid plaques were observed, we analyzed the temperate nature of these
phages by Blasting the MCP from each phage family against the extant protein database to
identify close phage relatives that were integrated in bacterial host genomes.82,83 Only Chronis
came up with a close (>90%) match, and had 100% matches in several Klebsiella pneumoniae
whole genome sequences deposited in NCBI’s Genbank.
Bacterial challenge assay
The ability of the fourteen bacteriophages to infect various clinical isolate host strains
was evaluated and presented Table 3, with only a unique few able to infect multiple isolates. Out
of the fourteen bacteriophages found against K. pneumoniae, Sibilus and KaAlpha had the
highest versatility and were effective against six of the seven host strains. The next phages that
were able to infect the majority of the clinical isolates were Alina, Chronis and NahiliMali. All
plaques were clear and combined with the genomic analysis above, indicate that the phages are
most likely lytic with the exception of Chronis.
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Table 2-3: List of clinical isolates and the phage that were able to infect them. Shaded cells
indicate infection was observed. Included is a summary of how many isolates a single phage can infect
(far right column) and the total number of phages a strain was susceptible to (bottom row).

2008030 1002002 1300761 1002235
KaAlpha
Potts1
KaOmega
Domnhall
IMGroot
Alina
Penguinator
KingDDD
Call
SegesCirculi
Chronis
Sibilus
NahiliMali
Emp27

Number of Infecting
Phages:

4

5

4

6

IHC

5

IHC

6

IHC

Number of
Strains Infected

5

6
4
0
1
1
5
1
0
2
1
4
6
4
1

Discussion
Hospital-acquired infections that are caused by K. pneumoniae are a human health
problem that are prevalent worldwide.49,84 Since antibiotic treatments have associated
restrictions, shortcomings and potential side effects, phage therapy is now being considered as a
potential treatment and prevention for bacterial infections.49,58 There are several potential
beneficial effects of phage therapy, including creating a “cocktail” of phages that have activity
against different bacterial pathogens, ability to infect multi-drug resistant pathogens, the
potential for minimal side effects, and wide distribution upon systemic administration.58 Another
crucial aspect of phage therapy is the ability of the phage to be applied directly to local
microflora without causing harm.85 One of the criticisms that phage therapy faces is the ability to
meet the “gold-standard” of efficacy. The lack of efficacy is likely caused by insufficient funds
particularly in terms of clinical trials.85 At present, there are few phage products that are
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currently in use, both in terms of commercial use (e.g., Pyophage, and Instiphage sold in the
former Soviet Union) and in the form of biocontrol (e.g., OmniLytics (UT, USA) and Micreos
Food Safety (The Netherlands)).
There are other things to consider in using phage therapy as treatment for bacterial
infections. The phages being considered for use need to be thoroughly investigated, including
determination of the mechanism of host recognition and resistance, determining the phage titer
needed to effectively lyse bacteria, or the genetic contents of the phages that could potentially
benefit the bacteria, such as antibiotic resistance genes or bacterial virulence factors. It may also
be advantageous to examine the bacteria for any genotypic differences within a species since
thousands of strains may exist between which the phages are able to distinguish. For example, K.
pneumoniae has many different capsule types that may affect the efficacy of phage adsorption to
the surface of a bacterium and may explain the differences in host infections reported herein. A
phage cocktail that is able to infect most of the common clinical pathogenic strains would be
optimal.
This study demonstrates that there are several phages that show some efficacy against
clinical isolates of carbapenem-resistant K. pneumoniae, including some that infect multiple
isolates. The bacteriophages Sibilus and Alina showed versatility against several different strains
of K. pneumoniae (five out of six). An optimal cocktail would contain phages that can infect all
of the common clinical isolates. Thus, Sibilus and Alina, combined with Call and IMGroot,
could be used to treat K. pneumoniae infections in a broad-spectrum cocktail that may infect
many clinical isolates. Additionally, a multi-pronged approach by using multiple, unrelated
phages to treat an infection, can prevent a bacterium from developing resistance. This study
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indicates some of the necessary careful characterizations (genomic and host range) needed for
phage therapy to transition from in vitro studies and into clinical studies.
Comparisons between phages shows that we can expect some of the virulence differences
found between phages to be a result of small genomic differences between phages. For example,
the large phage cluster labeled in blue (Domnhall, IMGroot, Alina, Penguinator, KingDDD, Call
and SegesCirculi) shows extremely high nucleotide similarity between phages. Six of the seven
phages in this cluster are capable of infecting at least one strain of CRE-Klebsiella, indicating
that the miniscule differences between the genomes must account for the difference in virulence
and host specificity. Phages Call, Alina and Penguinator are capable of infecting K. pneumoniae
strain 1002002 while phages Call, IMGroot and Domnhall are capable of infecting K.
pneumoniae strain 1300761. Most of the genomic variability between phages of this cluster is
found towards the end of the genome, which shows some rearrangements, inversions, repeats,
truncations and indels. Further lab work will be required to identify specific host-specificity
factors that account for the differences in phage virulence against these strains of Klebsiella, as
even with high nucleotide and proteomic similarity, we see that there is great variability in
virulence.
Phages NahiliMali and Sibilus have a high nucleotide similarity, yet Sibilus was capable
of infecting six of the seven strains tested while NahiliMali only infected four. In addition to the
four infected by NahiliMali, Sibilus infected K. pneumoniae strains 1002002 and IHC#1, while
neither was capable of infecting K. pneumoniae strain 1300761. There are three complete genes
that are present in one, but not both, of the two phages: Sibilus gp3 and gp52 and NahiliMali
gp21. All three amino acid sequences have blastp hits to hypothetical proteins from other phages,
indicating unknown functions for each. Instead, the variability in host infectivity is most likely
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explained by the putative tail fiber proteins (Sibilus gp51 and NahiliMali gp47), which often
recognize the host receptor thereby determining host specificity. The tail fiber from Sibilus is
smaller (1,641nucleotides, 546 amino acids) than that of NahiliMali (1,746 nucleotides, 587
amino acids). When aligned, the nucleotide sequences have >90% identity for the region that
aligns, which covers only the first 962 nucleotides of each sequence. This indicates that the
variability in the C-termini of the gene products is likely sufficient to account for the increase in
host-recognition by Sibilus, allowing it to infect more strains than NahiliMali. Emp27 is distantly
related to Sibilus and NahiliMali and represents its own sub-cluster. Emp27 shows much less
host-diversity, capable of infecting only one strain, IHC#1. Emp27 gp8 aligns to Sibilus gp51
(the putative tail fiber) with about 60% amino acid identity, but this similarity is only found in
the N-termini 60% of the polypeptides. The C-termini have no similarity, which again may
explain the limited host range of Emp27 compared to Sibilus.
While similarities are substantial within individual phage clusters there is significant
diversity between the clusters used in this study, with little to no recognizable similarity across
clusters’ nucleotide and amino acid sequences (i.e. Chronis and KaAlpha; or, Alina and Sibilus).
This is indicative of a wide diversity of genes capable of forming viable phages that infect K.
pneumoniae, a phenomenon that is common in phage biology.33,86 Genome rearrangement and
exchange is a fairly common event in the phage lifecycle, as can be observed here even within a
single cluster (Domnhall cluster), and occurs readily with the host chromosome.87,88 In
comparing the two phylogenetic trees (the SplitsTree and large terminase maximum-likelihood
tree) it appears that they may be telling two different stories regarding phage evolutionary
relationships: the phage Chronis has been placed in two different relative locations on the trees,
one based off of the whole proteome and the other based off of a single protein. It is likely that
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such genetic exchange events occurring promiscuously in the phages’ evolutionary spectrum
account for some of the limited genetic crossover seen between clusters and may explain the
apparent inconsistencies in the phylogenies. It is possible that phages following the temperate
lifecycle left behind certain genetic elements in the host chromosome and were later picked up
by new phages during infection. This can occur multiple times within a single phage genome
resulting in mosaicism and is at least minimally evident within these phages. Whether the
variations in phage infectivity can be explained by horizontal gene transfer or genetic drift (or
both) is not directly clear from the results obtained in this study and is beyond the scope the
paper. Nevertheless, many of the phages indicate versatility against a variety of CRE-K.
pneumoniae strains which may prove useful in a clinical setting.
Finally, the presence of many tRNA genes and DNA motifs in the phage genomes has
implications for their evolutionary story as well as clinical application. KaAlpha has 19 tRNA
genes, whereas one or two is common among phages.89 Phage genomes tend to be fairly dense
with coding sequences, thus the presence of so many tRNA genes is indicative of some
evolutionary fitness tradeoff that is—or was—beneficial for the phage. One such tRNA, with
anticodon 5’-UUU-3’ is among the most highly used of K. pneumoniae (fourth most frequent),
but among the lowest used of Mycobacterium tuberculosis. KaAlpha also has motif matches to
known M. tuberculosis operons, as well as a number of short nucleotide sequences that match
Mycobacteriaceae species. While it cannot be concluded with certainty, these results suggest a
possible host-change event by this phage, or at the very least some horizontal gene transfer
occurrences, which would be surprising for phages that infect such different hosts (Gramnegative versus an acid-fast bacterium). KaOmega similarly has a DNA motif matching a
Pseudomonas species integration host factor (IHF) protein used for recombination but could also
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be used by temperate phages to integrate into the host genome. KaOmega also has an abundance
of tRNA genes (20), which is unusual for a phage unless it uses genes with codon biases atypical
for the host. Some of the tRNA genes match the most highly used codons in K. pneumoniae.
Combined, the motif analysis and the presence of commonly used tRNAs is suggestive of a
possible host-change for KaOmega, as well. A recent host-change event could explain why
KaOmega was incapable of infecting the CRE strains in this study, even though it was isolated
on K. pneumoniae, as it may not be fully fit to infect variations in the host strain. Domnhall and
the other phages in the cluster do not carry tRNA genes, suggestive of long-term host interaction
and lack of need to carry their own tRNAs, which are instead abundant in the host cell.
Domnhall did, however, carry an interesting DNA motif matching a promoter sequence that
binds a transcription factor involved in activating multi-antibiotic resistance genes (MarA) in
Escherichia coli.90 The MarA protein has homologues in other Enterobacteriaceae family
species, as well, including K. pneumoniae. Phages have been shown to increase susceptibility to
antibiotic compounds even after resistance has developed, and phage therapies are most effective
when administered with low levels of antibiotics.63,91 The MarA-binding DNA motif found in
Domnhall and other members of its cluster (all except SegesCirculi) may suggest one such
mechanism for restoring susceptibility to antibiotic drugs, that by infecting the cell the MarA
transcription factors preferentially bind phage DNA, subsequently reducing transcription of
antibiotic-resistance operons in Enterobacteriaceae. Thus, Domnhall and its cluster are excellent
candidates for phage therapies of K. pneumoniae infections due to host specificity (and lack of
evidence suggesting a change of host) and possible host abatement, aside from inherent phage
virulence.
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The evidence herein supports that there are a variety of genetically distinct phages
capable of infecting unique antibiotic-resistant clinical isolates. In this study, fourteen phages
were evaluated on a genetic level and a functional level, for their ability to infect a variety of
CRE-Klebsiella strains. The results indicate that even among highly related phages, minute
differences in nucleotide or amino acid sequences can affect the host range of the phage. This
finding has important implications for clinical application of phage therapy, as individual phages
must be tested against specific strains to confirm virulence, since it cannot be predicted from
evaluating the phage genome alone, at this time. Furthermore, we identified certain genetic
elements that may contribute to phage virulence, mainly the presence of a DNA motif that would
competitively bind proteins used by Enterobacteriaceae for activation of multi-antibioticresistance genes. The presence of such elements may be critical in future applications of phage
therapy, as it allows for the combined usage of antibiotics and may increase their effectiveness.
While genetic differences help account for some of the differences in phage virulence against the
host, more research should be conducted in the future to identify specific phage proteins
responsible for host-recognition and specific host proteins that act as phage recognition sites.
Such studies will elucidate the phage-host interactions and functions of otherwise unknown
genes. In the meantime, genomic computational analyses serve to uncover some of the mysteries
found within phage genomes and help explain some of the nuances contributing to differential
virulence.
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Supplementary data

Supplementary Figure 1 (S1): Enlarged Phamerator Map
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Supplementary Figure 2 (S2): Enlarged SplitsTree Map
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Supplementary Table 1: ANI matrix of all fourteen phages.
1. KaAlpha

100.00

61.48

42.47

40.98

40.73

40.93

41.07

41.03

41.1

43.24

34.98

34.95

34.55

34.88

2. Potts1

61.48

100.00

42.36

40.8

40.77

40.88

40.94

40.91

40.92

43.1

34.94

34.58

34.25

35.09

3. KaOmega

42.47

42.36

100.00

38.61

38.51

38.68

38.85

38.8

38.79

40.52

33.83

33.51

33.23

33.87

4. Domnhall

40.98

40.8

38.61

100.00

93.33

93.70

94.67

95.65

95.23

87.56

43.9

42.99

42.21

44.09

5. IMGroot

40.73

40.77

38.51

93.33

100.00

92.51

97.94

93.29

95.67

86.65

44.01

42.99

42.21

44.14

6. Alina

40.93

40.88

38.68

93.70

92.51

100.00

94.38

95.18

94.69

88.84

43.96

42.92

42.22

44.05

7. Penguinator

41.07

40.94

38.85

94.67

97.94

94.38

100.00

95.28

97.72

88.72

44.35

43.28

42.51

44.34

8. KingDDD

41.03

40.91

38.8

95.65

93.29

95.18

95.28

100.00

95.93

89.12

44.2

43.14

42.38

44.22

9. Call

41.1

40.92

38.79

95.23

95.67

94.69

97.72

95.93

100.00

88.86

44.27

43.2

42.44

44.28

10. SegesCirculi

43.24

43.1

40.52

87.56

86.65

88.84

88.72

89.12

88.86

100.00

43.03

42.12

41.43

43.37

11. Chronis

34.98

34.94

33.83

43.9

44.01

43.96

44.35

44.2

44.27

43.03

100.00

32.94

32.57

33.12

12. Sibilus

34.95

34.58

33.51

42.99

42.99

42.92

43.28

43.14

43.2

42.12

32.94

100.00

92.8

63.06

13. NahiliMali

34.55

34.25

33.23

42.21

42.21

42.22

42.51

42.38

42.44

41.43

32.57

92.8

100.00

63.12

34.88

35.09

33.87

44.09

44.14

44.05

44.34

44.22

44.28

43.37

33.12

63.06

63.12

100.00

fourteen .
Emp27
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CHAPTER III: New Phages Infecting Pathogenic Bacillus anthracis
Authors: Trever Thurgood, Julianne H. Grose, Richard Robison
This chapter is an excerpt from a publication in preparation for submission at the time of writing
of this thesis.
Abstract
Bacillus anthracis is a well-studied bacterial species that has significant implications for
human and animal health. As a pathogen, B. anthracis has increasing mortality rates,
respectively, for each of its three routes of infection: cutaneous, gastrointestinal and respiratory.
Despite high virulence, however, B. anthracis has its own natural predators: bacteriophages
(phages). Phages are viruses that adsorb onto the surface of bacteria, inject their nucleic acid, and
lyse the cell or splice into the bacterial chromosome. There are few phages known to infect B.
anthracis, namely a select group of phages from the Wß-like cluster. In this study, a set of
newly-isolated B. anthracis phages is characterized, and their virulence tested against genetically
diverse strains of pathogenic B. anthracis. These are the first phages outside of the Wß-like
cluster reported as capable of infecting multiple pathogenic strains.
Introduction
Bacillus anthracis is an ancient pathogen well-known to humankind. B. anthracis was
first identified as the causative agent of anthrax by Robert Koch in 1876.1 Once the symptoms
and pathogen were formally associated with one another, researchers began to realize that
anthrax-like diseases had plagued humanity for millennia. Reports from ancient Greece, Egypt,
and China, as well as Europe in the middle ages, depict tales of diseases with symptoms identical
to anthrax.92–95 After its rediscovery, another early microbiologist, Louis Pasteur, created the first
animal anthrax vaccine. This vaccine has been used to protect against the disease, which has
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historically caused pestilence amongst livestock, livestock workers and workers in other animalbased professions.96,97 In 1954, the first human live-attenuated anthrax vaccine was developed,
but remains unavailable to the public and requires annual boosters to remain effective.98,99 In
contemporary history, B. anthracis has garnered attention due to its potential use as a bioterrorist
weapon.10,18 More recently, bioterrorist attacks in the United States have led to a surge in anthrax
research and its mechanisms of pathogenicity. Without rapid medical intervention, B. anthracis
infection has different mortality rates for the three routes of infection: cutaneous (20%),
gastrointestinal (50%), and inhalation (>80%).99
Bacillus anthracis is a member of the Bacillus cereus group, a small group of pathogenic
and non-pathogenic Bacillus species. B. anthracis is a Gram-positive, spore-forming bacteria
capable of causing severe infection in man and animal. Common to all Bacillus species are
general cell structure, essential metabolic components, and spore-forming capability. The outer
structure of the bacterial cell consists of a phospholipid bilayer membrane and a peptidoglycan
cell wall encompassing the periplasmic space (Fig. 1A). The peptidoglycan cell wall itself is a
complex structure essential for bacterial survival. Some of the functions of the peptidoglycan
layer include maintenance of cell turgor pressure, exclusion of extracellular enzymes and toxins,
and transport of metabolically important molecules.1,100 Peptidoglycan consists of repeating units
of N-acetylmuramic acid (NAM) and N-acetyl-glucosamine (NAG), interspersed with long
repeated chains of teichoic acid that extend through the cell wall as well as out into the
extracellular space (Fig 1B). Surrounding the outer edges of the peptidoglycan layer is the
surface layer (S-layer) which contains adhesion proteins and genus- and species-specific
proteins.101 Specific to pathogenic B. anthracis strains is an additional protective layer, the poly-
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A

Poly-D-Glutamic
Acid Capsule
S-layer (with teichoic
acid, glycoprotein and
carbohydrate subunits)

TA
Peptidoglycan (with
teichoic acid)
Periplasmic space
Phospholipid bilayer
(with membrane proteins)

C
B

Figure 3-1. Structure of Grampositive cell wall and B. anthracis
capsule. A, cartoon magnification of
the Gram-positive cell wall general
structure with some cell wallassociated components; B, N-acetylmuramic acid and N-acetylglucosamine structural linkage in
peptidoglycan, in addition to the
teichoic acid (TA) structure; C, polyD-glutamic acid capsule structure,
showing a single glutamic acid
molecule.

TA

D-glutamic acid capsule (PGAC), which plays a role in immune cell evasion when infecting a
host (Fig. 3-1C).102,103
Genetic similarity among Bacillus species is relatively high, with few, but critical genes
differentiating B. anthracis from other species of this genus. B. anthracis is distinguishable from
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other Bacillus species by its inactive flagellar components, rendering it nonmotile, as well as a
mutated, nonfunctional metabolic regulatory enzyme, PlcR, that plays a role in insect and plant
pathogenicity.104,105 ß-hemolysin, an enzyme capable of degrading red blood cells, and which is
active in most other Bacillus species is also nonfunctioning in B. anthracis. Additionally, the B.
anthracis genome contains four putative, inactive prophage regions not found in most other
Bacillus species.106 Furthermore, B. anthracis is distinguished from non-pathogenic species by
the presence of two virulence plasmids, pXO1 and pXO2. Full pathogenicity of B. anthracis is
dependent on these two plasmids, which encode a tripartite toxin known as the anthrax toxin and
the aforementioned PGAC, respectively. When a vertebrate host becomes infected with B.
anthracis, the PGAC prevents immune cells from phagocytosing the bacteria, while the tripartite
toxin disrupts host cell signaling pathways that lead to cell death and necrosis.10,17,107 The
severity and rate of disease onset of B. anthracis makes this bacterium a formidable pathogen.
Bacteriophages are naturally occurring viruses that infect and kill bacteria. Phages have
been shown to be viable candidates as an alternative approach to treating bacteria, particularly
antibiotic-resistant strains. Phages follow one of two viral lifecycles when infecting bacterial
host cells: lytic or lysogenic. The lytic lifecycle begins with phage recognition of and attachment
to host cell surface components. A phage can only recognize certain surface receptors, which
may limit the number of bacterial hosts it can infect, such as if there are differences between
species or strains. Typical receptors include trans-membrane proteins or signal receptors, though
surface enzymes, transport channels, pili, flagella, capsular elements, as well as teichoic acids in
Gram-positive hosts can serve as targets.34 After adsorption onto the cell surface, subsequent
enzymatic degradation of the bacterial cell wall allows for injection of viral nucleic acid into host
cytoplasm. In contrast to lytic phages, temperate phages cleave the host genome and insert
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themselves as dormant genetic parasites (also known as prophages once integrated into the host
genome) and may remain within the host genome indefinitely or until induced into the lytic
phase.
There are very few phages reported as capable of infecting a variety of B. anthracis
strains. The B. anthracis phages γ, Wß, Cherry and Fah have all been shown to be capable of
infecting encapsulated (pXO2-possessing) B. anthracis; however, these phages are genetically
similar and do not represent the diversity of B. anthracis phages.108–111 Interestingly, it has been
reported that the expression of the PGAC inhibits the ability of phages to recognize the
bacterium and may inhibit host lysis.36 To test the ability of genetically diverse phage lineages to
infect B. anthracis, we utilized a library of genetically diverse B. anthracis strains, as
characterized by Van Ert, et al., in concert with 18 phages from a newly-isolated collection in
our lab. Van Ert, et al., typed over one thousand isolates of B. anthracis and categorized the
genetic diversity of the strains into three phylogenetic groups, A, B and C, with twelve total
branches (Fig. 3-2).40 The 18 phages represent four clusters and six sub-clusters of B. anthracis
phages that extend beyond the Wß family (Fig. 3-3).
Materials and methods
Phage isolation
Soil samples were collected from various regions in the Western United States and
cultured with B. anthracis, Sterne for 48 hours at 30 ºC. One gram of soil was mixed with 10 mL
of Luria-Bertani broth (LB) and 1 mL of B. anthracis overnight culture grown in the same
medium. After the incubation period was complete, the samples were centrifuged at 4,000 x g for
50min., the supernatant removed and filtered with 0.45 μm syringe filters. Five μL of the filtered
supernatant was added to 500 μL of overnight B. anthracis culture and incubated at ambient
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Figure 3-2. Reproduction of phylogenetic tree representing B. anthracis genetic diversity. This
phylogenetic tree is a reproduction of the phylogenetic tree presented by Van Ert, et al. (2007), using
the SNPs from multi-locus variation sequences presented in their study. The evolutionary history was
inferred by using the Maximum Likelihood method and Tamura-Nei model. The tree with the highest
log likelihood (-71.75) is shown. The percentage of trees in which the associated taxa clustered
together is shown next to the branches. Initial tree(s) for the heuristic search were obtained
automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances
estimated using the Maximum Composite Likelihood (MCL) approach, and then selecting the
topology with superior log likelihood value. The tree is drawn to scale, with branch lengths measured
in the number of substitutions per site. This analysis involved 12 nucleotide sequences. There were a
total of 13 positions in the final dataset. Evolutionary analyses were conducted in MEGA X.

temperature for 45 minutes. Then, 4.5mL 1% molten LB top agar was added to the mixture,
which was then poured over LB agar plates. The plates were incubated at 30ºC for 48 hours and
checked for plaques. If plaques appeared on the plates, they were picked with a pipette tip and
resuspended in 200 μL LB broth, of which 50 μL was used to infect another 500 μL of overnight
B. anthracis culture and the same plating process was repeated. After the second round of
plating, plaques were picked, resuspended in 200 μL LB broth, of which 100 μL was used to
inoculate a 1:10 dilution of B. anthracis culture in LB broth, for a total of 10mL. The enrichment
culture was incubated with shaking at 30 ºC for 48 hours. After the incubation period, the same
centrifugation and filtration protocol was followed to obtain a purified high titer lysate. Phage
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titer was assayed using a serial dilution method by moving 100 μL into 900 μL sterile LB broth
until a 1:108 dilution was obtained. Fifty μL of the 102, 104, 106 and 108 dilutions were used to
infect 500 μL of overnight B. anthracis culture and plated in the same manner to determine the
concentration of phage in the lysate.
Phage sequencing
Once high titer lysates were obtained (minimum of 108 pfu/mL), phage DNA was
isolated with the Norgen Biotek Phage DNA Isolation Kit (Norgen, Canada). Phage DNA was
then digested with HindIII restriction enzyme for 1 hr at 37 ºC and the resulting digestions run on
1% agarose gel electrophoresis to visualize DNA banding patterns and check for diversity. If
phage banding patterns appeared unique on the gel, they were submitted for Illumina sequencing
at the Brigham Young University Sequencing Center (Provo, UT, USA). Phage genomes were
assembled using Geneious R8.1.65 Genome annotations and corrections were made manually
using DNA Master 4, Basic Local Alignment Search Tool (BLAST) 5 searches and GeneMark
coding potential prediction software.66
Genomic analysis
Genome comparisons were done by aligning phage nucleotide sequences on Gepard to
create the dot plot.67 The GenBank-formatted files of annotated genomes were used in tandem
with PhamDB in an online interface to generate a database usable by Phamerator, an open-source
program used to create pham maps.68,69 Kalign was used to generate average nucleotide identity
(ANI) tables for the phages.70 SplitsTree was used to create protein-based phylogenetic grouping
of the phages by exporting the pham table of conserved proteins (available on Phamerator) to

4
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http://cobamide2.bio.pitt.edu/
https://blast.ncbi.nlm.nih.gov/Blast.cgi
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Janus1, which converts the table to a nexus (.nex) file-type required for SplitsTree.71 The
maximum likelihood phylogenetic tree of the phages’ large terminase subunits was assembled
with MEGA X after aligning the amino acid sequences on Geneious R8.1.41,65
BSL-3 phage infection assay
Each strain selected for the infection assay was streaked from the frozen inventory of B.
anthracis strains onto LB plates and incubated at least 24 hr at 37 ºC. Liquid cultures were
created by inoculating LB broth (5-10 mL) with a single colony from the isoplates and these
were incubated with shaking at 37 ºC overnight. Then, in a biosafety cabinet, 500 μL aliquots of
the overnight cultures were placed into disposable plastic culture tubes. The aliquots were
infected with 50 μL aliquots of phage dilutions ranging from 100-10-4, incubated at ambient
temperature for 45 min and plated onto LB plates with 1% molten LB top agar. The plates were
allowed to solidify at least 10 min before being sealed in plastic bags, removed from the
biosafety cabinet and incubated at 37 ºC overnight. Plates were checked for plaques and plaque
counts recorded.
Results
Genomic analyses
Eighteen phages were isolated against the host B. anthracis, sequenced and annotated as
previously described. Dot plot analysis is a common method for comparing phage genomes due
to their highly mosaic nature and the ability of the dot plot to detect similarity in rearranged
genomes.80,83 The whole-genome dot plot assembled shows the phages are separated into four
clusters, or groups of phages with over 50% genome similarity, two of which have sub-clusters
of very closely related phages (Fig. 3-3). The cluster labeled in yellow is related to the Bacillus
phage known as TsarBomba. This cluster has four sub-clusters, each of which has Bacillus phage
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relatives, as revealed by comparing nucleotide sequences to phages deposited in GenBank. The
blue cluster is divided by two sub-clusters, but the entire cluster resembles B. anthracis phage
Tsamsa. There are two additional clusters consisting of phages with much smaller genomes than
the TsarBomba-like and Tsamsa-like phages and are predicted to be temperate phages. The last
cluster represented on the dot plot resembles genetically the Wß family known to infect B.
anthracis.

Figure 3-3. Gepard dot plot comparison of B. anthracis phage genomes. The phage names are
listed down the left side of the figure. On the graph, phages are separated by horizontal and vertical
blue lines, while clusters are separated by horizontal and vertical orange lines. Solid black, diagonal
lines indicate nucleotide similarity >50%. Clusters are represented with colored squares.

An analysis of the phage proteome confirmed the relationships seen by nucleotide
sequence comparison. Proteins were grouped by relatedness using Phamerator68,69, and
SplitsTree79 was used to create a phylogeny based off of protein homologues. The SplitsTree of
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the phages used in this analysis shows the protein-based grouping to match the nucleotide-based
grouping shown on the dot plot (Fig. 3-4). The cluster and sub-cluster groupings are very
distinct, and branching appears to have occurred distantly in the phages’ past. Similarly, a
genomic nucleotide and protein map generated in Phamerator shows individual nucleotide
sequence similarities between phages of the same cluster by highlighting between genomes (Fig.
3-5).68,69 Protein similarities are displayed with similarly-colored boxes. Differences between
otherwise highly related phages are made obvious by regions between genomes that are not
highlighted. There is little to no observable similarity between clusters by either SplitsTree of
Phamerator analysis.

Figure 3-4. SplitsTree comparing proteomic relatedness of B. anthracis phages. The phages
used for the infection assays are boxed in red, while the circles correspond to the phage clusters and
sub-clusters, as shown on the Gepard dot plot.
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McCartney
E-cubed
Emiliahah
Erita
ObiWanKenobi
Abinadi
JarJar
RonSwanson
Chewbecca
Casper
MrDarcy
Skywalker
Nate
Sophrita
McCartney cont.
E-cubed cont.
Emiliahah cont.
Erita cont.
ObiWanKenobi cont.
Abinadi cont.
JarJar cont.
RonSwanson cont.
Chewbecca cont.
Casper cont.
MrDarcy cont.
Skywalker cont.
Nate cont.
Sophrita cont.
Athena
McDreamy
Booya
McSteamy

Figure 3-5. Phamerator map of B. anthracis phages used in this study. The Phamerator map
highlights differences between the genomes of the phages in purple. Similar gene products from
conserved protein families are highlighted in similar colors. There is no observable similarity between
phages of different clusters.

Finally, the phages’ large terminase subunits were aligned using Geneious R8.1 and
submitted to MEGA X to create a maximum likelihood phylogenetic tree (Fig. 3-6). Not
surprisingly, the phylogenetic tree produced shows the same groupings predicted from the dot
plot, SplitsTree and Phamerator map, but does provide some insight into which phages may have
experienced more significant genetic drift at the protein level.
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Infection assays
The results of the infection
assays using the twelve pathogenic
strains of B. anthracis and eight of
the 18 phages we selected for this
study are presented in Table 1. One
phage was selected from each
Figure 3-6. Evolutionary analysis by Maximum Likelihood
method of phage large terminase subunits. The
evolutionary history was inferred by using the Maximum
Likelihood method and JTT matrix-based model. The tree
with the highest log likelihood (-8535.21) is shown. The
percentage of trees in which the associated taxa clustered
together is shown next to the branches. Initial tree(s) for the
heuristic search were obtained automatically by applying
Neighbor-Join and BioNJ algorithms to a matrix of pairwise
distances estimated using a JTT model, and then selecting the
topology with superior log likelihood value. The tree is drawn
to scale, with branch lengths measured in the number of
substitutions per site. This analysis involved 18 amino acid
sequences. There were a total of 678 positions in the final
dataset. Evolutionary analyses were conducted in MEGA X.

cluster or sub-cluster from our
collection to represent the phages’
genetic diversity. While the analysis
is still in progress, current results
show that every strain is susceptible
to a number of phages. Similarly,
each phage is capable of infecting a

Table 3-1. Strain susceptibility to phage infection. Strain numbers are listed across the top and
phage names down the left side of the table. Green cells indicate successful infection by the phage
observed as plaques. Gray cells indicate no infection observed. Strain 1055 has not yet been assayed.
The approximate phage titer is listed under the Sterne column.
34

39

102

158

193

293

402

442

462

488

489

McCartney

?
?
?
?
?
?
?
?

ObiWanKenobi

Abinadi
JarJar
Skywalker
Sophrita
McDreamy
Booya
Total number of
confirmed
infecting phages:

1055

3

6

7

8

7

7

2
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8

8

4

7

?

Total
number of
pathogenic
strains
infected:

10
10
10
8
6
7
8
8

Sterne
2e9
4e8
3e8
9e7
1e9
2e8
8e8
3e8

number of pathogenic strains, while no phage is capable of infecting all strains. The efficiency of
plating (EOP) is defined as the ratio between the highest titer obtained on the host strain (Sterne)
and the observed infecting titer on non-host strains and is not included in this analysis; however,
definitive decreases in infection efficiency (i.e. a ratio <1) have been observed during the course
of the infections.
Discussion
This analysis is intended to determine which genetically distinct clusters of phages are
capable of infecting a variety of B. anthracis isolates with a goal of producing an effective phage
therapy cocktail capable of treating an anthrax infection. While the study is still in progress, a
number of results indicate that indeed, many of the strains are susceptible to phage infection,
despite the observation by Negus, et al., that the PGAC inhibits phage infection. Observed
differences in the efficiency of phage infections on the pathogenic strains may be explained by
the presence of the capsule but may not account for the decreased infection efficiency of the
phages on the pathogenic strains of B. anthracis. Additional analysis may be required to
determine if the capsule or mutations in surface proteins are responsible for this difference. An
additional SplitsTree is included to show how genetically similar phages available on NCBI
relate to the phages of this study (Fig. 3-7). Phage phi29, a B. subtilis phage that bears no
nucleotide similarity to the B. anthracis phages of this study, is included as an outgroup. In
analyzing this SplitsTree it becomes clear that the proteomic diversity of the phages is
substantial. Interestingly, four phages from our collection from the Wß-like group, McDreamy,
Athena, Booya and McSteamy, appear to have more proteomic similarity to he intended
outgroup (B. subtilis phage phi29) than they do to the other B. anthracis phages. This could be
indicative of possible host changes in the course of the phages’ genetic history and may account
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Figure 3-7. SplitsTree of B. anthracis phages including previously-characterized phages.
Previously characterized phages are circled in red. Similar to the SplitsTree above (Fig. 4), there are
clear clusters established, based solely off of protein similarity in the phages. In this SplitsTree, the
outgroup, B. subtilis phage phi29, is more closely related to two of the cluster (Athena and McDreamy,
and Booya and McSteamy) than these clusters are to other B. anthracis phages.

for the broad host range of the phages observed in this study. (Similarly, Wß has a known broad
host range, which may also be explained by genetic divergence from other B. anthracis phages).
Strains 34 and 402 seem to be the most resistant to phage infection but are still susceptible to
infection from the TsarBomba-like family of phages. This indicates some genetic components
that increase the host range of this cluster of phages beyond that which is seen from other
clusters. Additional analysis of the genes contained in these phages is needed to elucidate the
permitting factors.
Future directions
Moving forward, there is still much to be learned from these phages. In contrast to
expected results, many of the phages are capable of infecting a variety of strains, and all strains
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used in this study are susceptible to at least one phage. While the PGAC does seem to inhibit
phage efficiency, it does not prevent phage infection. Perhaps for the strains that seem resistant
to a number of phages a higher phage titer is needed to penetrate the capsule. Yet, we see that
despite the genetic diversity represented by 11 of 12 strains used in this study, all strains are
susceptible to infection from phages outside of the Wß family. As the repository of phages grows
annually, perhaps a new cluster of phages will arise that is completely incapable of infecting the
variety of B. anthracis hosts.
Additional considerations moving forward that must be considered are the ability of these
phages to infect sporulated B. anthracis. The sporulated form has a completely different and
unique cell surface structure than either the avirulent Sterne strain or pathogenic strains exhibit.
One phage in particular, SBP8a, is known to infect sporulated B. anthracis.112 This phage bears
high nucleotide similarity to phage Abinadi used in this study (>95%) as determined by BLAST
nucleotide alignment, and minimal similarity to other phages in the same cluster (TsarBombalike). Thus, it can be expected that at least Abinadi will also be capable of infecting sporulated B.
anthracis.

54

CHAPTER IV: Clinical Application of Phage Therapy for Multi-Antibiotic-Resistant
Enterobacteriaceae Infections
Authors: Trever L. Thurgood, Julianne H. Grose
Abstract
Since the onset of the age of antibiotics, many millions of lives have been saved from the
application of antimicrobial compounds to otherwise terminal infections. Yet, with the use of
antibiotics comes the inevitability of antibiotic-resistance. Bacteria are living, adapting
organisms that are keen to adapt to environmental challenges, and unless alternative treatments
are rapidly developed and deployed to fight the dramatic increase in antibiotic-resistant bacterial
infections, current methods of treatment will rapidly become obsolete. Phage therapy is one such
alternative treatment that has shown to be effective a number of times. In 2018, our lab was
contacted for collaboration to prepare a number of phage therapies for multi-drug-resistant
antibiotic infections in both humans and animals. In accordance with Food and Drug
Administration guidelines, multiple phage therapies were prepared for treatment and are
currently in the process of delivery to treat these infections.
Introduction
A number of studies and reviews have analyzed in-depth the oncoming (or, perhaps, the
already-onset) crisis of antibiotic-resistant bacterial pathogens.25,27–30,37,113–115 The CDC has cited
this facet of public health as one of its top health concerns.24 As such, the responsibility of
finding alternative treatments to these all-to-common infections falls upon researchers.
Microbiologists have deployed a number of resources, one of which comes from nature itself.
Bacteriophages have been shown to be effective in treating antibiotic-resistant infections in a
number of cases, and show promise going into the future.57,116–120
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The focus of this thesis has so far been on phage molecular genetics and in vitro
experimentation of phage therapy on CRE isolates and other pathogenic species. In line with the
research methods and techniques developed during the course of this program of study, multiple
opportunities presented themselves to apply this research in a clinical setting. Beginning in the
summer of 2018, the Grose lab in the Department of Microbiology and Molecular Biology at
Brigham Young University (Provo, UT, USA) initiated collaborative efforts with doctors (and a
veterinarian) to begin identifying phages capable of treating several multi-drug-resistant bacterial
infections. Following stringent protocols, phage research can progress from the lab bench to the
hospital room.
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Protocol Number:

1

Create enrichment
culture from sewage

2

Plate lysate to find phage

3

Plaque purify phages 3x

4

Create high titer lysate

5

Use HTL to create large
liquid culture

6

Eliminate LPS from
culture

7,8

Titer test and assay
endotoxin levels

FDA approval and
administration
Figure 4-1. General Workflow for Phage Therapy Preparation.
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Materials and methods
Enrichment culture: amplify phage from sewage
Bacterial pathogens are abundant in sewage water, and where bacteria are abundant, so,
too, are phages. Thus, collection of sewage water is the initial step required for isolation and
identification of phages potentially capable of infecting antibiotic-resistant bacteria. To
accomplish this, aliquot 0.5mL of sewage samples into culture tubes in a biosafety cabinet. Then,
add 4mL LB broth before aliquoting 0.5mL host bacteria (overnight bacterial culture) into
sewage + broth mixture. Incubate 24-48 hours at 37°C, with shaking at ~200rpm.
Plaque assay
Using above enrichment culture, centrifuge for a minimum 30 minutes at 4,000 x g (4k x
g) to pellet bacterial cells and debris. Decant supernatant into a clean tube and repeat a 30-minute
centrifugation at the same speed. Decant the supernatant again into a clean tube. Use 50uL of the
centrifuged lysate to infect 500uL bacterial host for 30 minutes at room temperature. After
incubation, add 4.5mL molten LB top agar (LB TA) to the phage infection and pour over an LB
agar plate. Incubate overnight between room temperature and 37°C. Check for plaque formation,
indicating viable phage presence. Alternatively, a spot test can be done by mixing 0.5mL
bacterial host with 4.5mL molten LB TA and pouring over LB agar plate. After setting at least
10 minutes, spot 5uL phage lysate onto plate. Incubate overnight between room temperature and
37°C. Check for plaque formation, indicating viable phage presence.
Plaque purification
Using a sterile micropipette tip, gently touch a single plaque in the center with the end of
a pipette tip. Resuspend the phage in 100uL LB by gently swirling and shaking the pipette tip in
the LB broth to create a plaque pick suspension. If plaques are too small to pick with a pipette
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tip, an alternative is pipetting 10uL sterile LB broth onto the plaque, waiting 10-20 seconds, and
decanting the liquid into LB broth for a liquid plaque pick phage resuspension. If using the liquid
plaque pick, for best results, the suspension should be centrifuged either at 4k x g for 5 minutes
or at full speed on a tabletop centrifuge for 30 seconds before proceeding. Create a dilution series
by diluting the 100uL phage suspension into 900uL LB broth, creating a 1:101 dilution. Mix by
very gentle vortexing, pipetting or tapping on the desk. Decant 100uL of the 1:10 dilution into
900uL LB broth for a 1:102 dilution. Repeat this decanting and resuspending until desired
dilution factor is obtained (typically 104 for plaque picks and 108 for high titer lysates). Using 24 dilutions from the series, infect 500uL aliquots of bacterial host with 50uL phage dilutions (i.e.
one aliquot of bacteria will be infected with the 102 dilution and one aliquot with the 104 dilution,
etc.). Incubate at room temperature for 30 minutes. Add 4.5mL molten LB TA to the phage
infection and pour over LB agar plates. Incubate overnight between room temperature and 37°C.
Check for plaque formation. Alternatively, a spot test may be performed using the same protocol
described above. This portion of the procedure (plaque purification) must be completed 3 times
before phage can be considered “purified” from sewage samples. This is to ensure removal of
superfluous viral/bacterial/toxin particles.
Create high titer lysate (HTL)
To create a high titer phage lysate, dilute 0.5mL overnight bacterial culture into 4.5mL
LB broth. Then, the bacterial culture was inoculated with a plaque pick suspension by pipetting
100uL of the plaque pick suspension into the bacterial culture. Incubate a minimum of 6 hours at
37°C shaking at ~200rpm. Centrifuge culture for 30 minutes at 4k x g and decant supernatant
into a clean tube. Centrifuge supernatant again at 30 minutes, 4k x g. Create dilution series and
do a plaque assay to determine the titer.
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Create large culture
Large cultures are created because large numbers of virions are needed for a successful
phage therapy treatment. Aliquot 5mL overnight bacterial culture into 45mL sterile LB broth.
Inoculate bacterial culture with 2-5mL phage HTL. Incubate a minimum of 6 hours at 37°C
shaking at ~200rpm. Add 2-3mL chloroform to lyse bacterial cells and liberate additional phage
particles; continue shaking ~30 minutes. Centrifuge culture at 4k x g for a minimum of 1 hour.
Decant supernatant into clean tubes. Test phage titer via plaque assay or spot test.
Purify phage of LPS
Once a phage culture is successfully separated from bacterial cultures, the lysate is still
contaminated with bacterial endotoxin. Lipopolysaccharides (LPS) are endotoxins expressed on
the surface of Gram-negative bacteria and are shed into the medium while the bacteria are
dividing. Even when bacteria are centrifuged and filtered from a culture, LPS still contaminates
the lysate. LPS is a powerful inducer of the innate immune system in vertebrate species, and can
lead to septic shock and subsequent death.44,45 Thus, proper removal from the phage lysate is
imperative for the safety and success of the therapy. Fortunately, a number of protocols have
been developed for proper removal, and commercial kits are available to test the concentration of
LPS in prepared samples.47,121 For every 30mL clean lysate add 7.5mL PEG-8000, 2.5M NaCl.
Incubate on ice for at least 30 minutes. Spin at 12,000 x g to pellet phage. Decant and discard
supernatant. Centrifuge again 2-3x (5min) to collect remaining PEG-8000 mixture at the bottom
of the tube; decant and discard. Resuspend phage in 10mL phospho-buffered saline (PBS; pH
7.4). Plate 1mL onto LB agar plates to test sterility of the resuspended phage solution.

60

Titer test
Assay phage titer after resuspension using serial dilution and plaque assay method
mentioned above.
Assay for LPS
Assay the concentration of LPS in the resuspended lysate using the ToxinSensorTM
Chromogenic LAL Endotoxin Assay Kit. As per the protocol on company website, begin by
carefully dispensing 100 µl of standard or test sample into endotoxin-free vials. 6 All samples
should be mixed thoroughly for 30 seconds with a vortexer. Avoid foaming/bubbles. Each test
must include a blank as well as at least four endotoxin standards in duplicate. The blank sample
vial contains 100 μl of LAL Reagent Water instead of test sample. Add 100 µl of reconstituted
LAL to each vial. Cap the vials and mix well by swirling gently. If the endotoxin concentration
in sample is expected in the range of 0.01 - 0.1 EU/ml, incubate the rack with all vials at
37°C±1°C for T1 using a water bath or heating block. If the endotoxin concentration is expected
in the range of 0.1 - 1 EU/ml, incubate at 37°C±1°C for T2. Note: The optimal value of T1 and
T2 should be referred to the label on the kit. After proper incubation, add 100 µl of reconstituted
chromogenic substrate solution to each vial. Cap the vials and swirl gently to mix well. Do not
shake or vortex to avoid foaming. Incubate at 37°C±1°C for 6 minutes. Add 500 µl of
reconstituted Color-stabilizer #1 (Stop Solution) to each vial and swirl gently to mix well. Do not
shake or vortex to avoid foaming. Add 500 µl of reconstituted Color-stabilizer #2 to each vial
and mix well. Finally add 500 µl of reconstituted Color-stabilizer #3 to each vial. Gently swirl
each vial to mix well. Bubbles must be avoided. Read the absorbance of each reaction vial at
545nm using distilled water as blank to adjust the photometer to zero absorbance.

6

https://www.genscript.com/product/documents?cat_no=L00350&catalogtype=Document-PROTOCOL
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Because phage therapy is not approved for clinical use in the United States, even if these
steps are completed with accuracy and precision, the Food and Drug Administration must review
each request for phage therapy on a case-by-case basis. Therefore, all protocols and preparation
data must be stringently recorded and sent to the FDA for approval before use.
Creating phage frozen stock
Dissolve glycerol in distilled H2O to create a 40% stock solution. Aliquot 600uL 40%
glycerol into cryovials. Autoclave the 40% glycerol-containing cryovials on the liquid cycle
(121°C, 20 min.). Once cooled, add 1mL phage lysate with high titer to the 40% glycerol, to
create a final concentration of 15% glycerol. Cap and mix well by inverting cryovial. Store at 80°C.
Pulling from phage frozen stock
Dilute overnight culture of bacterial host 1:1 in LB broth. Pick a small ice chunk from
frozen stock and suspend in the bacterial culture. Incubate overnight at 37°C, with shaking
~200rpm. Centrifuge the lysate at 4k x g for 30 minutes in microcentrifuge tube. Decant the
supernatant and proceed with dilution series.
Results
Mycobacterium tuberculosis
The hunt for phages to treat an antibiotic-resistant infection began in summer 2018. A
young patient with cystic fibrosis had a M. tuberculosis infection in their lungs and the doctors
were seeking alternative treatment via phage therapy. While a number of mycobacteriophages
were in their possession, none infected the strain and could not be used. In order to assist with
their efforts, our lab sent a number of sewage samples from our vast library of previously
collected sewage to the researchers overseeing the case.
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Klebsiella pneumoniae
Similarly, a patient with a persistent urinary tract infection (UTI) caused by K.
pneumoniae also sought alternative treatment for their infection. A collection of over a dozen
phages from the Grose lab was sent to the research team only to discover that none of them
infected the strain and were thus inadequate for phage therapy. Similarly, collections from other
labs around the world contributed their phages to treat the infection but only a single phage in
nearly one hundred partially infected the strain. To circumvent this problem, the multi-resistant
strain was sent to the lab and used with our collection of international sewage samples to culture
any phages capable of infecting the strain. Out of dozens of samples, only one produced a phage
capable of infecting the strain. Once the phage was identified, the plaque purification protocol
was followed, and a small sample of the phage lysate was sent to the research team. At this time,
the infection has somewhat subsided so as to render phage therapy unnecessary until the
infection worsens (again due to lack of government approval for this type of treatment).
Citrobacter freundii
Soon after the contact was made for
assistance in treatment of the K.
pneumoniae infection, another request came
for treatment of a Citrobacter freundii
infection. This time, however, the patient
was a well-known sea turtle at an aquarium
in Florida, named Shelley. Shelley had had
an infection in her carapace and shell for
over two years (Fig. 4-2). The infection was

Figure 4-2. Shelley the sea turtle shell infection.
This photo was obtained from the Mote Marine
Laboratory and Aquarium in Sarasota, FL from the
caretakers of Shelley to demonstrate the severity of
her condition.
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starting to affect her behavior, so the veterinarian reached out. A similar process was followed in
identifying phages using sewage samples. This time two sewage samples yielded phages. Once
the phages were identified and plaque purified, phage samples were prepped directly for
treatment using the above protocols. The phages were prepped, tested for LPS concentrations,
and sent to Florida for the treatment of the turtle, who is reported to be doing well.
Serratia marcescens
Finally, and perhaps most seriously, a request came in for phage therapy treatment of a
Serratia marcescens infection that has been festering in a patient’s leg for an extended period of
time. The nature of the infection is that it intensifies, then ebbs with the administration of
antibiotics, only to return again. While the antibiotics have limited effectiveness in treating the
infection, the patient and doctors seek to eradicate the unwanted pathogen. For this they have
turned to phage therapy, to administer in tandem with antibiotics, which seems to be the most
effective treatment method.91 Identifying phages necessary for treatment followed a similar
isolation protocol as previously mentioned. Five phages in total were found to be effective
against the strain. While the phages were being prepared, however, the bacterial strain seemed to
lose virulence and the effectiveness of the phages began to decrease. Eventually, the bacteria was
totally nonviable and another isolate had to be requested from the doctors treating the patient.
This loss of viability was likely due to the lack of antibiotics in culturing the bacteria.
Interestingly, this particular strain is susceptible to a number of antibiotics, with limited
resistance to common laboratory antibiotics, such as ampicillin. Fortunately, however, culturing
the bacteria with antibiotics the second time around maintained virulence and proved effective
enumerating the phages. The phage cultures were purified of LPS and tested for endotoxin a
number of times. Most kits are calibrated for LPS concentrations to be quite low (maximum of 1
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endotoxin unit per mL). Unfortunately, while effective enough for clinical application, the LPS
purification protocol written above does not remove LPS below this level. It was learned in the
process of purification and LPS-level testing that samples must be diluted 10,000-fold or more
before testing for endotoxin levels in order to gain an accurate number from the assay.
Discussion
This study has shown that identifying phages capable of infecting antibiotic-resistant
bacterial strains is not only possible, but a viable option for treatment of multi-resistant
infections. The process of isolating, identifying, enumerating, and purifying phages from
environmental samples is a strenuous and mildly dangerous process (due to repeated exposure to
known resistant bacteria), but may become the norm for treatment of bacterial infections. While
phages may never have the convenience and simplicity of mass-produced antibiotic compounds,
they will always have the reliability of antimicrobial activity. Phages, like bacteria, are adapting
organisms, so even when a bacterium develops resistance to a single phage, the phage responds
by developing a new infection mechanism. The co-evolutionary relationship of bacteria and their
phages has been described as an “evolutionary arms race”.33,122 As researchers, we can utilize
this arms race to develop an arsenal of phages capable of infecting even the most resistant
bacterial infections, and ultimately
save lives.
Figure 4-3 shows a map of
the United States where the sewage
samples

that

produced

San Francisco,
CA

Provo, UT
Spanish Fork, UT

Leesburg, VA

Los Angeles, CA
Mesa, AZ

viable

phages against antibiotic-resistant
bacterial strains was obtained from.

Figure 4-3. Map showing location of sewage samples that
produced phages capable of infecting antibiotic-resistant bacterial
strains. The majority of the samples were collected from the Western
United States in 2018, while one came from the East coast.
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CHAPTER V: Conclusion
Review
Despite their size, bacteriophages are incredibly diverse organisms that are constantly
teaching us new things about the fundamentals of biology. The genetic reservoir of phages has
proven to be an abundant source of knowledge in elucidating the underlying mechanisms that
drive biological processes. Additionally, phages have proven to be clinically useful in a number
of settings. In this collection of studies, phage genetics has been reviewed extensively for a set of
unique phages found to have interesting applications. Phages of Klebsiella pnuemoniae, Bacillus
anthracis, Citrobacter freundii and Serratia marcescens have all been reviewed, and each has
added a piece to the puzzle of biology that we, as researchers, seek to assemble.
In reviewing the proceedings of this thesis, it becomes clear that while some questions
have been answered, even more questions have arisen. The relationship between phage and
bacterium is complex and extensive, and it seems that we have only begun to uncover the
underlying mechanisms that drive biological processes. Yet, the data included in this thesis have
attempted to provide some satisfactory answers to these mysteries. From underlying genetics to
clinical application of phage biology, the utility of phages is great in our efforts to learn.
From the phages of K. pneumoniae, certain genetic elements, such as promoter regions
mimicking the host promoters, may be found in phages that could play a role in decreasing
virulence. DNA sequences are essential for taking over host metabolic machinery. The new B.
anthracis phages can be characterized based on similarity to phages in online databases, and
their characterization can also provide clues into the underlying biology of what permits phage
infections of this species. Finally, while many aspects of phage mechanisms remain unknown,
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they can be harnessed for the eradication of bacterial infections. Thus, while not all is known,
they can still be useful for biologists.
Future directions
Moving forward, additional questions need to be answered in an effort to learn more
about phage biological processes and molecular mechanisms. The completion of the B. anthracis
phage infection assays is necessary to understand how the genetic diversity of these phages
affects interaction with the host. RNAseq analysis on phages capable of infecting antibioticresistant bacterial strains will provide insight into the functions of proteins necessary for host
takeover. Bioinformatic analyses on the variety of phages of all hosts will continue to reveal
unique and unknown aspects of phage genomes that will provide additional research questions
for future microbiologists. In sum, our search for answers will undoubtedly lead to additional
questions, as we seek to uncover the mysteries of phage-bacteria interactions.
To elucidate some of the underlying processes of the phages used to infect K.
pneumoniae clinical isolates, tail fibers of the successful phages can be cloned into unsuccessful
phages via homologous recombination to see if progeny can now infect the species of interest.
Furthermore, there could be components of the bacterium responsible for preventing phage
infection, such as DNA degradation post-injection, or degradation of some essential phage
protein. A similar explanation may be found in B. anthracis. The strains used in this study nearly
cover the complete genetic diversity of global B. anthracis strains, therefore some variability in
phage infections is expected. Further characterization of the genetic variation could explain
phage efficiency. Additionally, phage components may exist that specifically allow for capsulebinding, capsule-degrading or spore-binding and spore-degrading mechanisms that are yet to be
characterized. No matter the case, however, there are many doorways opened by these findings.
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